Bioterrorism and children: Unique concerns with infection control and vaccination

Anesthesiology Clinics of North America

Volumn 22, Issue 3, 2004, Pages 563-577

  Leissner, Kay B ^a,b   Holzman, Robert S ^a,b   McCann, Mary Ellen ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTITOXIN; CHLORAMPHENICOL; CIDOVIR; CIPROFLOXACIN; DOXYCYCLINE; GENTAMICIN; PENICILLIN G; RIBAVIRIN; SMALLPOX VACCINE; STREPTOMYCIN; TOXIN; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS VACCINE;

AIRBORNE INFECTION; ANTHRAX; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; BIOSAFETY; BOTULISM; CLINICAL FEATURE; CLOSTRIDIUM BOTULINUM; CORRELATION ANALYSIS; EBOLA VIRUS; ENCEPHALOMYELITIS; ERYTHEMA MULTIFORME; FEVER; FRANCISELLA TULARENSIS; HEALTH CARE SYSTEM; HEALTH SURVEY; HUMAN; HYPERSENSITIVITY REACTION; INFECTION CONTROL; INFECTION SENSITIVITY; LAW ENFORCEMENT; PATHOGENESIS; PERICARDITIS; PLAGUE; PUBLIC HEALTH; RASH; REVIEW; RISK ASSESSMENT; SMALLPOX; SMALLPOX VIRUS; STEVENS JOHNSON SYNDROME; TULAREMIA; UNITED STATES; VACCINATION; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION; VIRUS TRANSMISSION; WASTE MANAGEMENT;

BIOTERRORISM; CHILD; HUMANS; INFECTION CONTROL; PUBLIC HEALTH; VACCINATION;

EID: 4344703595     PISSN: 08898537     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atc.2004.04.004     Document Type: Review

References (46)

1. Anonymous Update. Investigation of bioterrorism-related inhalational anthrax-Connecticut, 2001. MMWR Morb Mortal Wkly Rep. 50:2001;1049-1051
2. Noah D., Huebner K., Darling R., Waeckerle J. The history and threat of biological warfare and terrorism. Emerg Med Clin North Am. 20:2002;255-271
3. Sidell F., Franz D. Overview: defense against the effects of chemical and biological warfare agents. Sidell F., Takafuji E., Franz D. Textbook of Military Medicine. 1997;1-7 Borden Institute, Washington, DC
4. Committee on Environmental Health and Committee on Infectious Diseases for the American Academy of Pediatrics Chemical-biological terrorism and its impact on children: a subject review. Pediatrics. 105:2000;662-670
5. Khan A., Leavitt A., Sage M. Biologic and chemical terrorism: strategic plan for preparedness and response, recommendations of the CDC strategic planning workgroup. MMWR Morb Mortal Wkly Rep. 49:2000;1-14
6. Centers for Disease Control and Prevention Recognition of illness associated with the intentional release of a biologic agent. JAMA. 286:2001;2088-2090
7. Mackay B. SARS poses challenges for MDs treating pediatric patients. CMAJ. 168:2003;1457
8. McKeever P., O'Neill S., Miller K. Managing space and marking time: mothering severely ill infants in hospital isolation. Qual Health Res. 12:2002;1020-1032
9. Girouard S., Levine G., Goodrich K., Jones S., Keyserling H., Rathore M., et al. Infection control programs at children's hospitals: a description of structures and processes. Am J Infect Control. 29:2001;145-151
10. Siegel J. Controversies in isolation and general infection control practices in pediatrics. Semin Pediatr Infect Dis. 13:2002;48-54
11. Inglesby T., O'Toole T., Henderson D. Preventing the use of biological weapons: improving response should prevention fail. Clin Infect Dis. 30:2000;926-929
12. Cherry C., Kainer M., Ruff T. Biological weapons preparedness: the role of physicians. Intern Med J. 33:2003;242-253
13. Gerberding J., Hughes J., Koplan J. Bioterrorism preparedness and response: clinicians and public health agencies as essential partners. JAMA. 287:2002;898-900
14. Richards C., Burstein J., Waeckerle J., Hutson H. Emergency physicians and biological terrorism. Ann Emerg Med. 34:1999;183-190
15. Brinsfield K., Gunn J., Barry M., McKenna V., Dyer K., Sulis C. Using volume-based surveillance for an outbreak early warning system. Acad Emerg Med. 8:2001;492
16. Wagner M., Tsui F.-C., Espino J., Dato V., Sitting D. The emerging science of very early detection of disease outbreaks. J Public Health Manag Pract. 7:2001;50-58
17. Lazarus R., Kleinman K., Dashevsky I., Adams C., Kludt P., DeMaria A.J., et al. Use of automated ambulatory-care encounter records for detection of acute illness clusters, including potential bioterrorism events. Emerg Infect Dis. 8:2002;753-760
18. Lazarus R., Kleinman K., Dashevsky I., DeMaria A.J., Platt R. Using automated medical records for rapid identification of illness syndromes; the example of lower respiratory infection. BMC Public Health. 1:2001;1-9
19. Macintyre A., Christopher G., Eitzen E.J., Gum R., Weir S., DeAtley C., et al. Weapons of mass destruction events with contaminated casualties: effective planning for health care facilities. JAMA. 283:2000;242-249
20. Garner J. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 17:1996;53-80
21. Seto W., Tsang D., Yung R., Ching T., Ng T., Ho M., et al. Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). Lancet. 361:2003;1519-1520
22. Borio L., Inglesby T., Peters C., Schmaljohn A. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA. 287:2002;2391-2405
23. Neely M., Toltzis P. Infection control in pediatric hospitals. Curr Opin Infect Dis. 14:2001;449-453
24. Wehrle P., Posch J., Richter K., Henderson D. An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull World Health Organ. 43:1970;669-679
25. Anonymous Update. Management of patients with suspected viral hemorrhagic fever-United States. MMWR Morb Mortal Wkly Rep. 44:1995;475-479
26. Henderson D., Inglesby T., Bartlett J., Ascher M., Eitzen E., Jahrling P., et al. Smallpox as a biological weapon: medical and public health management [consensus statement]. JAMA. 281:1999;2127-2137
27. Warfield K., Bosio C., Welcher B., Deal E., Mohamadzadeh M., Schmaljohn A., et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA. 100:2003;15889-15894
28. Oplinger A. NIAID Ebola vaccine enters human trial. Available at: http://www.niaid.nih.gov/newsroom/releases/ebolahumantrial.html. Accessed November 25, 2003
29. Wharton M., Strikas R., Harpaz R., Rotz L., Schwartz B., Casey C., et al. for th Advisory Committee on Immunization Practices Healthcare Infection Control Practices Advisory Committee. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep. 52:2003;1-16
30. Centers for Disease Control Office of Communication, Media Relations Smallpox vaccination program status by state. Available at: http://www.cdc.gov/ od/oc/media/spvaccin.htm. Accessed February 26, 2004
31. Dixon C. Smallpox in Tripolitania, 1946: an epidemiological and clinical sudy of 500 cases including trials of penicillin treatment. J Hygiene. 46:1948;351-377
32. Rotz L., Dotson D.A., Damon I., Becher J. Vaccinia (Smallpox) Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Morb Mortal Wkly Rep. 50(RR10):2001;1-25
33. US Census Bureau American FactFinder. Available at: http://factfinder. census.gov/servlet/QTTable?ds_name=DEC_2000_SFI_U&geo_id=0100. Accessed November 7, 2003
34. Eichner M. Analysis of historical data suggests long-lasting protective effects of smallpox vaccination. Am J Epidemiol. 158:2003;717-723
35. Lane J., Ruben F., Neff J., Millar J. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis. 122:1970;303-309
36. Lane J., Ruben F., Neff J., Millar J. Complications of smallpox vaccination, 1968. N Engl J Med. 281:1969;1201-1208
37. Neff J., Lane J., Fulginiti V., Henderson D. Contact vaccinia- transmission of vaccinia from smallpox vaccination. JAMA. 288:2002;1901-1905
38. Cono J., Casey C., Bell D. Smallpox vaccination and adverse reactions. guidance for clinicians. MMWR Recomm Rep. 52(RR04):2003;1-28
39. Waecker N.J., Hale B. Smallpox vaccination. What the pediatrician needs to know. Pediatr Ann. 32:2003;178-181
40. Fenner F., Henderson D., Arita I., Jezek Z., Ladnyi I. Smallpox and its eradication. Available at: http://www.who.int/emc/diseases/smallpox/ Smallpoxeradication.html. Accessed December 30, 2003
41. Nanning W. Prophylactic effect of antivaccinia gamma-globulin against post-vaccinial encephalitis. Bull World Health Organ. 27:1962;317-324
42. Polak M., Beunders B., Van Der Werff A., Sanders E., Klaveren J., Brans L. A comparative study of clinical reaction observed after application of several smallpox vaccines in primary vaccination of young adults. Bull World Health Organ. 29:1963;311-322
43. Centers for Disease Control Interim Smallpox fact sheet. Smallpox vaccine and heart problems: information for people who have recently received the smallpox vaccine. Available at: http://www.bt.cdc.gov/agent/smallpox/ vaccination/cardiacrecentvaccinees.asp. Accessed March 2, 2004
44. Centers for Disease Control Supplemental recommendations on adverse events following smallpox vaccine in the pre-event vaccination program: recommendations of the Advisory Committee on Immunization Practices. JAMA. 289:2003;2064
45. Finkel E. Australia. Engineered mouse virus spurs bioweapon fears. Science. 291:2001;585
46. Elias P. Vaccine-Evading Mousepox Virus Created. Available at: http://www.washingtonpost.com/ac2/wp-dyn/A47612-2003Oct31?language=printer. Accessed Oct. 31, 2003